Humanizing CAR T-cell therapy in B-ALL

Humanizing CAR T-cell therapy in B-ALL

Saved in:

Bibliographic Details
Main Authors:	Rawan Faramand, Lori Muffly
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Series:	Blood Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952925001156
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL
by: Jordan Gauthier, et al.
Published: (2025-04-01)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01)

Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study
by: Jing Yang, et al.
Published: (2025-01-01)

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
by: Hannah Lust, et al.
Published: (2025-06-01)

Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia
by: CAO Jinjin, DU Juan, QU Shanna, ZHU Mingyu, WANG Yang, HU Han, LIU Binlei
Published: (2025-05-01)

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
by: Barbara D. Friedes, et al.
Published: (2025-01-01)

Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B
by: Lu Cao, et al.
Published: (2025-06-01)

CAR-T CELL THERAPY IN CLL
by: Selver Kurt
Published: (2024-12-01)

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma
by: Alejandro Luna, et al.
Published: (2025-04-01)

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma
by: Annette Künkele, et al.
Published: (2025-04-01)

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
by: Wei Liu, et al.
Published: (2024-04-01)

Tailoring CAR surface density and dynamics to improve CAR-T cell therapy
by: Michael Hudecek, et al.
Published: (2025-04-01)

CAR-T Cell Therapy for Solid Tumors
by: Liz T. Tony, et al.
Published: (2025-01-01)

CAR-T CELL THERAPY IN ACUTE LEUKEMIAS
by: Serhat Çelik
Published: (2024-12-01)

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01)

Correction: Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma
Published: (2025-07-01)

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
by: Evgenii Shumilov, et al.
Published: (2025-08-01)

Breaking Age Barriers: The Benefits of CAR T-Cell Therapies in Treating Large B-Cell Lymphoma in Older Patients
by: Frank Stenner, et al.
Published: (2023-12-01)

Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
by: Gaoxiang Wang, et al.
Published: (2025-03-01)

Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL
by: Jennifer Bolsée, et al.
Published: (2025-05-01)

CAR-T Cell Therapy: Revolutionizing Cancer Treatment
by: Kirolos Eskandar, et al.
Published: (2024-02-01)

Influence of CAR T-cell therapy associated complications
by: Mohammad Mussab Umair, et al.
Published: (2025-02-01)

Rare Adverse Events of CAR T-Cell Therapy
by: Antonia Müller
Published: (2024-03-01)

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies
by: Belén Sierro-Martínez, et al.
Published: (2025-08-01)

Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy
by: Ning Li, et al.
Published: (2025-05-01)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
by: Anett Pfeiffer, et al.
Published: (2018-09-01)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
by: Sophia Stock, et al.
Published: (2025-01-01)

Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy
by: Yoganand Balagurunathan, et al.
Published: (2024-11-01)

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2024-11-01)

Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma
by: Andrew J. Portuguese, et al.
Published: (2025-06-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY
by: Ulrike Bacher, et al.
Published: (2021-01-01)

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
by: Bohan Zhang, et al.
Published: (2025-02-01)

CAR-armored-cell therapy in solid tumor treatment
by: Yan Liu, et al.
Published: (2024-11-01)

CAR-T cell therapies: patient access and affordability solutions
by: Elisabete Gonçalves
Published: (2025-12-01)

Cost-effective strategies for CAR-T cell therapy manufacturing
by: Luiza Abdo, et al.
Published: (2025-06-01)

CAR-based cell therapies for systemic lupus erythematosus
by: Yiyang Wang, et al.
Published: (2025-03-01)

Dasatinib for treatment of CAR T-cell therapy-related complications
by: Jakob R Passweg, et al.
Published: (2022-12-01)

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
by: Qingyang Zhang, et al.
Published: (2020-01-01)

CAR-T cell a potential platform for cancer therapy
by: Azad Kumar Maurya, et al.
Published: (2025-03-01)